ChromaDex Report issue

For profit Phase 2
Founded: Irvine CA United States (1999)
Status: Acquired by LabCorp (2017)

Organization Overview

First Clinical Trial
2014
NCT02191462
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

ChromaDex, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

nicotinamide (6 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Inflammation (Phase 2)

Peripheral Nervous System Diseases (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 1